Glaucoma Research

Glaucoma Associates is dedicated to advancing treatment and knowledge in our field through high quality clinical trials. Participation is often one way patients can contribute toward our future. Patients are compensated for their time. If you would like more information about enrolling in one of our  studies, please contact our Research Coordinators, Casie Goldman at 503-413-6505 or at clinicaltrials@deverseye.org. Casie will be happy to answer any questions you may have.

Current Trials - Enrollment Open

Patients with Elevated Intraocular Pressure

  • We are recruiting persons for research studies examining new drops or treatments for glaucoma and ocular hypertension.  Please contact us if you have Open Angle Glaucoma or Ocular Hypertension in both eyes with baseline intraocular pressures in the mid to high 20’s with or without your eye drops. The testing and examinations are free and there is compensation for time. 

Portland Progression Project

  • We are enrolling up to 100 additional participants for the P3 Study. This is an ongoing study funded through the National Institutes of Health (NIH) that Devers has pioneered for over 20 years. We examine blood flow, new visual field tests, and testing of the optic disc to detect glaucoma earlier and change in glaucoma over time. This study will last a minimum of 4 years. Participants will have 2 study visits a year. Each study visit will last approximately 2 hours. There is compensation for your time.

ASSISTS Study

  • We are looking for patients with uncontrolled glaucoma with a single existing glaucoma tube shunt implant. This study will compare outcomes of patients who undergo a second aqueous shunt vs patients who undergo transscleral diode laser cyclophotocoagulation (TLC)

Eye Drop Instillation Success and Adherence with Glaucoma Treatment

  • We are looking for patients who have difficulty using their eye drops, or difficulty administering the drops every day. We have two newly developed devices.  One aims to help doctors see how well patients are using their drops and the second aims to help patients use their drops more safety and effectively.